SOHO 2022 | The role of ibrutinib in DLBCL and the value of next-generation BTK inhibitors
Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the role of ibrutinib in the treatment of diffuse large B-cell lymphoma (DLBCL), and further highlights the Smart Start study (NCT02636322), which is evaluating the efficacy of ibrutinib in combination with lenalidomide and rituximab in patients with DLBCL. Dr Westin also comments on the growing importance of next-generation Bruton’s tyrosine kinase (BTK) inhibitors, and where these may fit in the treatment landscape of DLBCL. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Kite/Gilead, BMS, Novartis, Genentech/Roche, Morphosys/Incyte, AstraZeneca, Janssen, Calithera, and ADC Therapeutics, and consulting with Kite/Gilead, BMS, Novartis, Genentech/Roche, Morphosys/Incyte, AstraZeneca, Janssen, Calithera, ADC Therapeutics, Merck, and MonteRosa.
